Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Mar, 2033
(9 years from now) | |
US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) | |
US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) | |
US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 30, 2024 |
New Indication (I) | Aug 5, 2025 |
NCE-1 date: 2023-07-31
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
16
United States
14
European Union
5
Poland
5
Slovenia
5
Finland
5
Japan
5
Denmark
5
Hungary
5
Spain
5
Portugal
4
Korea, Republic of
4
Brazil
4
Lithuania
4
China
4
RS
4
Croatia
3
Canada
3
Ukraine
3
Australia
3
Israel
2
Chile
2
Hong Kong
2
Cyprus
2
Mexico
2
EA
2
South Africa
1
Georgia
1
Luxembourg
1
Netherlands
1
Malaysia
1
Argentina
1
New Zealand
1
Colombia
1
Norway
1
San Marino
1
Russia
1
Peru
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic